medigraphic.com
ISSN 0016-3813 (Impreso)

2018, Número 4

<< Anterior Siguiente >>

Gac Med Mex 2018; 154 (4)


La psoriasis: de la investigación básica y clínica al desarrollo de nuevos tratamientos

Esquivel-García R, Estévez-Delgado G, Rodríguez-Orozco AR, Ochoa-Zarzosa A, García-Pérez ME

Idioma: Español
Referencias bibliográficas: 45
Paginas: 502-508
Archivo PDF: 1782.86 Kb.


RESUMEN

La psoriasis es una enfermedad cutánea incurable que afecta a 2.9 % de la población mexicana, por lo que es trascendente analizar el impacto de la medicina traslacional en el desarrollo de medicamentos antipsoriásicos. En esta revisión se discuten conceptos etiopatogénicos de la enfermedad y se analizan artículos publicados entre 2005 y 2017 en torno a medicamentos en desarrollo, además, se presenta un análisis crítico sobre las perspectivas futuras en el desarrollo de nuevos tratamientos. El uso de estrategias bidireccionales de la medicina traslacional ha permitido incrementar significativamente el número de tratamientos antipsoriásicos disponibles. Se encontraron 18 nuevos fármacos en exploración. La caracterización de antígenos responsables de la activación inmunológica, la identificación de biomarcadores predictivos de eficacia farmacológica, el desarrollo de modelos más representativos de la enfermedad, así como la integración de aspectos farmacogenómicos a estrategias de medicina traslacional fueron identificados como elementos relevantes que deben ser incorporados en el desarrollo de nuevas opciones terapéuticas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.

  2. International Psoriasis Council. [Sitio web]. IPC psoriasis review. Dallas, Texas: IPC; 2009. p. 1-12. [Consultado 2017 Sep 10]. Disponible en: http://www.psoriasiscouncil.org/docs/ipcpsoriasisreview_dec_2009_ english.pdf?LanguageID=EN-US

  3. Kurd SK1, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891–5.

  4. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. S3-Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10:S1-S95.

  5. Dubertret L, Mrowietz U, Ranki A, Van-De-Kerkhof PC, Chimenti S, Lotti T, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006; 155:729-736.

  6. Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol. 1996; 35:710-719.

  7. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;9:302-309.

  8. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866-873.

  9. Guttman-Yassky E, Krueger JG. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol. 2007;157:1103-1115.

  10. Hébert HL, Ali FR, Bowes J, Griffiths CE, Barton A, Warren RB. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol. 2012;166:474-482.

  11. Das S, Stuart PE, Ding J, Tejasvi T, Li Y, Tsoi LC, et al. Fine mapping of eight psoriasis susceptibility loci. Eur J Hum Genet. 2015;23:844-853.

  12. Hawkes JE, Nguyen GH, Fujita M, Florell SR, Callis Duffin K, Krueger GG, et al. microRNAs in psoriasis. J Invest Dermatol. 2016;136:365-371.

  13. Picascia DD, Garden JM, Freinkel RK, Roenigk HH. Resistant severe psoriasis controlled with systemic cyclosporine therapy. Transplant Proc. 1988;20:58-62.

  14. Griffiths CE, Voorhees JJ. Cyclosporine A in the treatment of psoriasis: a clinical and mechanistic perspective. J Invest Dermatol. 1990;95:S53-S55.

  15. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1:442-447.

  16. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest. 1996;98:1878-1887.

  17. Gottlieb AB, Lebwohl M, Totoritis MC, Abdulghani AA, Shuey SR, Romano P, et al. Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J Am Acad Dermatol. 2002;47:692-700.

  18. Nickoloff BJ, Karabin GD, Barker JN, Griffiths CEM, Sarma V, Mitra RS, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol. 1991;138:129-140.

  19. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-390.

  20. Victor FC, Gottlieb AB. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol. 2002; 1:264-275.

  21. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez- Fariñas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183-3194.

  22. Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs. 2014;28:S15-S23.

  23. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-1132.

  24. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207-1211.

  25. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006;27:17-23.

  26. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000; 13:715-725.

  27. Di-Cesare A, Di-Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339-1350.

  28. Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009;10:1236-1242.

  29. Roblin D, Yosipovitch G, Boyce B, Robinson J, Sandy J, Mainero V, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015; 95:542-548.

  30. Balak DMW, Van-Doorn MBA, Rissmann R, Sullivan T, Burggraaf J, Arbeit RD. Results from a randomized, double-blind, placebo-controlled, monotherapy trial of IMO-8400 demonstrate clinical proof-of-concept for Toll-like receptor 7, 8, and 9 antagonism in psoriasis. J Am Acad Dermatol. 2015;72:AB247.

  31. Krueger JG, Suárez-Fariñas M, Cueto I, Khacherian A, Matheson R, Parish LC, et al. A randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis. PLoS ONE. 2015;10 e0142081.

  32. ClinicalTrials.gov. [Sitio web]. Study to assess the safety, tolerability and pharmacokinetics and pharmacodynamics of AZD0284 in healthy subjects. [Consultado 2017 Sep 10]. Disponible en: https //clinicaltrials.gov/ ct2/show/NCT02976831?term=AZD0284&rank=2

  33. David M, Gospodinov DK, Gheorghe N, Mateev GS, Rusinova MV, Hristakieva E, et al. Treatment of plaque-type psoriasis with oral CF101: data from a phase II/III multicenter, randomized, controlled trial. J Drugs Dermatol. 2016;15:931-938.

  34. Bantia S, Parker C, Upshaw R, Cunningham A, Kotian P, Kilpatrick JM, et al. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes. A novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies. Int Immunopharmacol. 2010;10:784-790.

  35. ClinicalTrials.gov. [Sitio web]. Efficacy and safety of namilumab (MT203) for plaque psoriasis. [Consultao 2017 Sep 10]. Disponible en: https:// clinicaltrials.gov/ct2/show/NCT02129777?term=Namilumab&rank=1

  36. Vaclavkova A, Chimenti S, Arenberger P, Holló P, Sator PG, Burcklen M, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 2 trial. Lancet. 2014; 384:2036-2045.

  37. ClinicalTrials.gov. [Sitio web]. Study to investigate the safety, tolerability, absorption, distribution, metabolism, and elimination of RWJ-445380 administered to patients with plaque psoriasis. [Consultado 2017 Sep 10]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT00396422?term= RWJ-445380&rank=1

  38. Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67:658-664.

  39. Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/ JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174:1266-1276.

  40. Ludbrook VJ, Hicks KJ, Hanrott KE, Patel JS, Binks MH, Wyres MR, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol. 2016;174:985-995.

  41. Bissonnette R, Luchi M, Fidelus-Gort R, Jackson S, Zhang H, Flores R, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J Dermatol Treat. 2016;27:332-338.

  42. ClinicalTrials.gov. [Sitio web]. Study of the efficacy, safety and tolerability of oral CEP-701 in patients with severe psoriasis. [Consultado 2017 Sep 10]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT00236119? term=Lestaurtinib&cond=psoriasis&rank=1

  43. Papp KA, Pariser D, Catlin M, Wierz G, Ball G, Akinlade B, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015;173:767-776.

  44. ClinicalTrials.gov. [Sitio web]. Paired psoriasis lesion, comparative, study to evaluate MOL4239 in psoriasis. [Consultado 2017 Sep 10]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT01826201?term=MOL4239&rank=1

  45. Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014;111:16814-16819.




2020     |     www.medigraphic.com